Scientists at the University of Nottingham, UK, have conducted a short-term intervention study to explore the effectiveness of a very low-calorie diet and Semaglutide, individually and in combination, in reducing body weight and controlling blood glucose in patients with type 2 diabetes. The findings of this study have been published in the journal Clinical Nutrition . Study: Metabolic effects of very-low calorie diet, Semaglutide or combination of the two, in individuals with type 2 diabetes mellitus .
Image Credit: Caroline Ruda / Shutterstock Type 2 diabetes is a multifactorial disease characterized by high blood glucose levels and insulin resistance. Impaired insulin secretion from pancreatic beta-cells is the leading cause of type 2 diabetes. Overweight and obesity are the major risk factors for diabetes development, affecting 90% of type 2 diabetic patients.
While obesity has been found to increase the risk of diabetes development by 7-fold, overweight has been found to be associated with insulin resistance and beta-cell dysfunction. Glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide is an antidiabetic medication with favorable efficacy in reducing body weight. A very low-calorie diet (VLCD) is another effective weight loss intervention with a promising ability to restore beta-cell function and improve glycemic control in type 2 diabetes.
In this study, scientists have explored the effects of VLCD and Semaglutide, both individually and in combination, on body.